These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33417061)

  • 21. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unilateral Capecitabine-related Hand-foot Syndrome.
    Matsuda S; Koketsu H; Hayakawa M; Nagata N
    Intern Med; 2015; 54(21):2779. PubMed ID: 26521911
    [No Abstract]   [Full Text] [Related]  

  • 23. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
    Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
    Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
    Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
    Trials; 2022 May; 23(1):420. PubMed ID: 35590388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
    Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
    Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
    Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
    Elyasi S; Shojaee FSR; Allahyari A; Karimi G
    Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
    Zhao J; Zhang X; Cui X; Wang D; Zhang B; Ban L
    Oncol Res; 2020 Feb; 28(1):103-106. PubMed ID: 31558182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
    Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Single-Blinded Phase II Trial Comparing Efficacy and Quality of Life of Topical Aloe Vera Gel Plus Urea Cream Versus Urea Cream Alone for Prevention of Hand Foot Syndrome in Cancer Patients Receiving Capecitabine.
    Wanichtanom L; Vrakornvoravuti G; Boonsiri M; Suthepwanon A
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):2203-2210. PubMed ID: 38918684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
    Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
    Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
    Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine and Hand-foot Syndrome: A Case Report.
    Uppala PK; Varghese AM; Yella SST; Velmurugan H; Thangaraju P; Krishna Sasanka KSBS
    Infect Disord Drug Targets; 2023; 23(1):e140622205973. PubMed ID: 35708076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
    Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
    Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
    Fujii C; Imamura H; Fukunaga M; Kamigaki S; Kimura Y; Kawase T; Kawabata R; Fujino M; Iseki C; Hamaguchi Y; Yamamoto E; Ishizaka T; Hachino Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2457-9. PubMed ID: 24394143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
    Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.